|
Market Closed -
Other stock markets
|
Pre-market 05:02:31 pm | |||
| 56.34 USD | -4.83% |
|
57.88 | +2.74% |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark | CI |
| 30/06 | CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovering, Developing and Commercializing Therapies | 91Cr | 11.98L | 37Cr | 3.73Cr | 35.1L | |||||
Total Assets | 275.19Cr | 224.31Cr | 222.96Cr | 224.2Cr | 226.52Cr | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | 18.7L | -3L | 28.88L | 35.87L | 36.34L | |||||
CAPEX | -8.17Cr | -3.72Cr | -94.7L | -19.01L | -9L | |||||
EBT | 38Cr | -65Cr | -15Cr | -36Cr | -58Cr | |||||
D&A | 1.8Cr | 2.42Cr | 1.98Cr | 1.93Cr | 1.95Cr | |||||
Operating Income | 37Cr | -67Cr | -22Cr | -47Cr | -66Cr | |||||
Net Income | 38Cr | -65Cr | -15Cr | -37Cr | -58Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
- Stock Market
- Stocks
- CRSP Stock
- Financials CRISPR Therapeutics AG
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition